IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
30.00
+1.40 (4.90%)
Nov 4, 2024, 4:00 PM EST - Market closed
IDEAYA Biosciences Employees
IDEAYA Biosciences had 124 employees as of December 31, 2023. The number of employees increased by 21 or 20.39% compared to the previous year.
Employees
124
Change (1Y)
21
Growth (1Y)
20.39%
Revenue / Employee
$31,629
Profits / Employee
-$1,436,452
Market Cap
2.53B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
iRhythm Technologies | 2,000 |
Amphastar Pharmaceuticals | 1,761 |
Twist Bioscience | 919 |
GoodRx Holdings | 694 |
ACADIA Pharmaceuticals | 598 |
Arrowhead Pharmaceuticals | 525 |
Geron | 141 |
Structure Therapeutics | 93 |
IDYA News
- 11 hours ago - IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PRNewsWire
- 3 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 7 days ago - IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - PRNewsWire
- 10 days ago - IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium - PRNewsWire
- 6 weeks ago - Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate - Benzinga
- 6 weeks ago - IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma - PRNewsWire
- 6 weeks ago - IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 - PRNewsWire